	US 11,905,253 B2
	Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility
Pierre Vacher, Bordeaux (FR); Patrick Legembre, Rennes (FR); Mickael Jean, Rennes (FR); Patrick Blanco, Bordeaux (FR); and Pierre Van De Weghe, Rennes (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); UNIVERSITE DE RENNES 1, Rennes (FR); CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, Talence (FR); INSTITUT BERGONIE, Bordeaux (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITE DE BORDEAUX, Bordeaux (FR)
Appl. No. 17/049,680
Filed by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); UNIVERSITE DE RENNES 1, Rennes (FR); CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, Talence (FR); INSTITUT BERGONIE, Bordeaux (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITE DE BORDEAUX, Bordeaux (FR)
PCT Filed Apr. 19, 2019, PCT No. PCT/EP2019/060242 § 371(c)(1), (2) Date Oct. 22, 2020, PCT Pub. No. WO2019/206834, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 18305500 (EP), filed on Apr. 23, 2018.
Prior Publication US 2021/0238143 A1, Aug. 5, 2021
Int. Cl. C07D 233/64 (2006.01); A61P 37/00 (2006.01); A61K 45/06 (2006.01)

CPC C07D 233/64 (2013.01) [A61K 45/06 (2013.01); A61P 37/00 (2018.01)]

19 Claims

1. A compound comprising N-acylated-N-aminoethyl amino acids, selected from the group consisting of:

or one of its salts;

said compound being in all the possible racemic, enantiomeric and diastereoisomeric isomer forms.